Who is sponsoring NCT03288129?

NCT03288129 is sponsored by Eisai Inc..

What condition does NCT03288129 study?

NCT03288129 studies Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures.

What is the status of NCT03288129?

NCT03288129 is currently COMPLETED.

Last reviewed 2022-05-16 · How we verify

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129 PHASE4 COMPLETED Results posted

This study will assess the retention rate of perampanel when given as monotherapy or first adjunctive therapy in participants with partial-onset seizures or primary generalized tonic clonic seizures. The study consists of 4 periods: a Screening Period (to start no earlier than 6 weeks before the first dose of study drug), a Titration Period (up to 13 weeks), a Maintenance Period (39 weeks), and a Follow-Up Period (4 weeks).

Details

Lead sponsor	Eisai Inc.
Phase	PHASE4
Status	COMPLETED
Enrolment	54
Start date	Wed Aug 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Partial Onset Seizures
Secondarily Generalized Seizures
Primary Generalized Tonic-Clonic Seizures

Interventions

Perampanel

Countries

United States